<DOC>
	<DOCNO>NCT00427401</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) PF-00915275 follow administration adult human subject T2DM 4-weeks . The primary end point glucose lowering ( 24 hour mean glucose concentration ) .</brief_summary>
	<brief_title>A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetes mellitus HbA1c &gt; 7.5 % . Recent ( within past 12 month ) evidence history unstable concomitant disease . Treatment oral hypoglycemic agent within 3 month enrollment . The exception criterion subject currently take metformin hydrochloride , stable dose ( change dose ) treatment diabetes within past 3 month longer enrollment may participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>